[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341661-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341661-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","validity-reliability-responsiveness-and-clinically-meaningful-change-threshold-estimates-of-the-national-comprehensive-cancer-network-functional-assessment-of-cancer-therapy-breast-cancer-symptom-index-nfbsi-16-research-article","Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) - Research article","","Study evaluated psychometric performance of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) subscales for advanced/metastatic breast cancer (aBC). Using data from 101 participants in the phase II Xenera-1 trial, the work tested subscale structure, convergent and known-groups validity, test-retest reliability, and responsiveness to improvement and worsening. Anchor-based clinically meaningful change thresholds were estimated to support interpretation at group and individual levels.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/validity-reliability-responsiveness-and-clinically-meaningful-change-threshold-estimates-of-the-national-comprehensive-cancer-network-functional-assessment-of-cancer-therapy-breast-cancer-symptom-index-nfbsi-16-research-article/341661/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/validity-reliability-responsiveness-and-clinically-meaningful-change-threshold-estimates-of-the-national-comprehensive-cancer-network-functional-assessment-of-cancer-therapy-breast-cancer-symptom-index-nfbsi-16-research-article/341661.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the NFBSI-16 evaluation?","Question",{"text":63,"@type":64},"To assess NFBSI-16 subscale structure, validity, reliability, and responsiveness in aBC and to estimate clinically meaningful change thresholds for score interpretation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which methods were used to evaluate validity and reliability?",{"text":68,"@type":64},"Validity used scale-level convergent validity and known-groups evidence, while reliability used test-retest analysis across specified trial cycles.",{"name":70,"@type":61,"acceptedAnswer":71},"How were meaningful change thresholds estimated and for which scores?",{"text":72,"@type":64},"Anchor-based methods (supported by distribution-based approaches) estimated meaningful change thresholds for DRS-P and Total scores at multiple cycles.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341661,1790192512,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clarke et al. Journal of Patient-Reported Outcomes (2024) 8:97  \n[https://doi.org/10.1186/s41687-024-00776-y](https://doi.org/10.1186/s41687-024-00776-y)  \nJournal of Patient-Reported Outcomes  \nRESEARCH Open Access  \nValidity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)  \nNathan A. Clarke 1*, Brendon Wong2, Rachael Lawrance 1, Anders Ingelgård2, Ingolf Griebsch2, David Cella3 and Andrew Trigg 1  \nAbstract  \nBackground Breast cancer is one of the most common cancers in women. Patient-reported outcome measures are used to evaluate patients’ health-related quality of life in clinical breast cancer studies. This study evaluated the structure, validity, reliability, and responsiveness of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) subscales in a clinical trial featuring patients with advanced/metastatic breast cancer (aBC), and estimated NFBSI-16 meaningful change thresholds.  \nMethods Data from 101 patients with aBC enrolled in a phase II trial (Xenera-1) were included for psychometric evaluation of the NFBSI-16 . Subscale structure was evaluated by assessing inter-item correlations, item-total correlations, and internal consistency (cycles 2 and 5) . Validity was assessed using scale-level convergent validity (cycles 2 and 5) and known-groups (Baseline) . Reliability was analysed via test-retest at cycles 3–4, and responsiveness to improvement and worsening was evaluated at cycles 5, 7, and 9. Meaningful change thresholds were estimated using anchor-based methods (supported by distribution-based methods) at cycles 5, 7, and 9.  \nResults NFBSI-16 internal consistency was acceptable, but item-total correlations suggested that its subscalesand the GP5 item (side-effect of treatment) scores may be preferred over a total score. Convergent and knowngroups evidence supported NFBSI-16 validity. Test-retest reliability was good to excellent for Total and DRS-P (disease-related symptoms: physical) scales, and moderate for the GP5 item. Responsiveness to worsening was generally demonstrated, but responsiveness to improvement could not be demonstrated due to limited observed improvement. Anchor-based meaningful change thresholds were estimated for DRS-P and Total scores.  \n*Correspondence:  \nNathan A. Clarke [nathan.clarke@adelphivalues.com](nathan.clarke@adelphivalues.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nClarke et al. Journal of Patient-Reported Outcomes (2024) 8:97 Page 2 of 11  \nConclusion This study provides evidence that the NFBSI-16 has desirable psychometric properties for use in clinical studies in aBC. It also provides estimates of group-and individual-level meaningful change thresholds to facilitate score interpretation in future aBC research.  \nKeywords Advanced breast cancer, NFBSI-16, Psychometric, Meaningful change, Minimal important difference, Patient-reporte","cbCaib415EfwONGd","https://ap.wps.com/l/cbCaib415EfwONGd","pdf",1283470,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n# Methods\n## Data source","[{\"question\":\"What was the main purpose of the NFBSI-16 evaluation?\",\"answer\":\"To assess NFBSI-16 subscale structure, validity, reliability, and responsiveness in aBC and to estimate clinically meaningful change thresholds for score interpretation.\"},{\"question\":\"Which methods were used to evaluate validity and reliability?\",\"answer\":\"Validity used scale-level convergent validity and known-groups evidence, while reliability used test-retest analysis across specified trial cycles.\"},{\"question\":\"How were meaningful change thresholds estimated and for which scores?\",\"answer\":\"Anchor-based methods (supported by distribution-based approaches) estimated meaningful change thresholds for DRS-P and Total scores at multiple cycles.\"}]","Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) - Research article | PDF",1790043070,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/831ca28bc934cfd06a963abb531a8c1e.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea2174eaf2e2b599c9a30cbcde75690f.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd22196cda92e95fe8de44a5e8e2eff8.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92bffe9b0ac55346973fba3750847fac.webp",980,1306]